Navigation
Navigation

Capricorn Health-tech Fund

The Capricorn Health-tech Fund (CHF) focuses on human health-technology investments. Health-technologies relate to the prevention, the diagnosis and the treatment of diseases.

Nexstim sells first NBT® system in Germany for depression therapy and research

News
- 22/05/2019
Helsinki, Finland: 22 May 2019 - Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depressive Disorder (MDD), announces that it…
Read more

Nexstim enters depression therapy market in Sweden

News
- 10/05/2019
Helsinki, Finland: 10 May 2019 - Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depressive Disorder (MDD), announces that its…
Read more

Team
Dr Jos B. Peeters
Chairman of the Executive Committee - Responsible for venture capital, finance and IT
Dr Katya Smirnyagina
Executive Director Capricorn Health-tech Fund

Portfolio

Success stories

Ogeda

Ogeda [Belgium] is a drug development company with a chemistry service business focusing on discovery of small molecules targeting GPCRs.